Stock TSVT 2SEVENTY BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights 2seventy bio, Inc.

Equities

TSVT

US9013841070

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
4.59 USD +7.87% Intraday chart for 2seventy bio, Inc. -1.29% +7.49%
Apr. 19 US FDA mandates label updates on CAR-T cancer therapies RE
Apr. 05 Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
US FDA mandates label updates on CAR-T cancer therapies
RE
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer
RE
U.S. FDA allows expanded use of Bristol Myers' cell therapy
RE
U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio?S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
CI
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc..
CI
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc. for $15 million.
CI
2seventy Bio Shares Soar Premarket as FDA Panel Backs Abecma
DJ
Bristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee Approval
DJ
FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy
CI
US FDA panel votes in favor of expanded use of Bristol Myers' CAR-T therapy
RE
2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapy
DJ
US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies
RE
Earnings Flash (TSVT) 2SEVENTY BIO Posts Q4 Revenue $10.7M, vs. Street Est of $15.2M
MT
2seventy bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
2seventy bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
North American Morning Briefing : S&P 500 Futures -2-
DJ
Bristol Myers: FDA to study Abecma as a treatment for myeloma
CF
Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
CI
North American Morning Briefing : Stock Futures -2-
DJ
Correction to 2seventy to Sell R&D Pipeline Article
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TSVT Stock
  4. News 2seventy bio, Inc.
  5. Highlights